NCT01692899View on ClinicalTrials.gov

Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

CompletedOBSERVATIONAL
Enrollment

780

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Rheumatoid Arthritis
Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

scientific steering committee of KOL in rheumatology

UNKNOWN

lead

Pfizer

INDUSTRY

NCT01692899 - Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice | Biotech Hunter | Biotech Hunter